2.12
-0.07 (-3.2%)
-0.07 (-3.2%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 107,047 |
|
|||||
| News | - | ||||||
| Day High | 2.1666 | Low High |
|||||
| Day Low | 2.08 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| InflaRx NV | IFRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.07 | -3.2% | 2.12 | 00:00:13 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.15 | 2.08 | 2.1666 | 2.12 | 2.19 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 428 | 107,047 | $ 2.11 | $ 226,382 | - | 0.7762 - 5.6856 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 144 | $ 2.12 | USD |
Period:
Draw Mode:
InflaRx NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 93.71M | 44.20M | 39.81M | $ - | $ - | -1.25 | -2.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | - |
InflaRx NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IFRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.79 | 2.80 | 2.08 | 2.38 | 119,106 | -0.67 | -24.01% |
| 1 Month | 2.24 | 2.91 | 2.08 | 2.53 | 128,704 | -0.12 | -5.36% |
| 3 Months | 1.45 | 3.18 | 1.22 | 2.10 | 473,122 | 0.67 | 46.21% |
| 6 Months | 2.46 | 3.18 | 0.7762 | 1.87 | 378,185 | -0.34 | -13.82% |
| 1 Year | 2.80 | 5.6856 | 0.7762 | 3.56 | 1,010,784 | -0.68 | -24.29% |
| 3 Years | 2.90 | 9.70 | 0.7762 | 4.19 | 709,046 | -0.78 | -26.9% |
| 5 Years | 15.19 | 53.10 | 0.7762 | 5.50 | 569,848 | -13.07 | -86.04% |
InflaRx NV Description
| InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |